PARI Pharma GmbH

Savara Inc. granted inducement awards to four new employees, including options for 80,000 shares and RSUs for 70,000 shares, under the 2021 Inducement Equity Incentive Plan.

Molgramostim showed significant improvement in disease severity score (DSS), DLCO% responder analysis, SGRQ Total Score, and GGO score compared to placebo at Weeks 24 and 48 in aPAP patients, according to IMPALA-2 trial data presented at ERS 2024.